Deutsche Bank Ag\ Krystal Biotech, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 15,611 shares of KRYS stock, worth $2.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,611

Previous 12,270 27.23%

Holding current value

$2.78 Million

Previous $2.25 Million 25.97%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$174.7 - $213.66 $583,672 - $713,838	3,341 Added 27.23%	15,611 $2.84 Million
Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $82,531 - $98,981	-539 Reduced 4.21%	12,270 $2.25 Million
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $650,328 - $1.08 Million	-6,021 Reduced 31.98%	12,809 $2.28 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $511,776 - $683,913	5,331 Added 39.49%	18,830 $2.34 Million
Q3 2023 Nov 09, 2023	BUY	$108.51 - $130.22 $39,606 - $47,530	365 Added 2.78%	13,499 $1.57 Million
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $329,537 - $547,213	-4,199 Reduced 24.23%	13,134 $1.54 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $283,551 - $330,085	3,917 Added 29.2%	17,333 $1.39 Million
Q4 2022 Feb 13, 2023	BUY	$63.14 - $79.9 $73,558 - $93,083	1,165 Added 9.51%	13,416 $1.06 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $129,505 - $164,552	-1,997 Reduced 14.02%	12,251 $854,000
Q2 2022 Aug 11, 2022	SELL	$48.93 - $73.47 $43,107 - $64,727	-881 Reduced 5.82%	14,248 $936,000
Q1 2022 May 13, 2022	BUY	$51.99 - $72.11 $9,930 - $13,773	191 Added 1.28%	15,129 $1.01 Million
Q4 2021 Feb 11, 2022	BUY	$39.81 - $88.24 $23,209 - $51,443	583 Added 4.06%	14,938 $1.04 Million
Q3 2021 Nov 04, 2021	SELL	$52.01 - $71.77 $17,423 - $24,042	-335 Reduced 2.28%	14,355 $749,000
Q2 2021 Aug 11, 2021	BUY	$62.14 - $81.82 $51,265 - $67,501	825 Added 5.95%	14,690 $999,000
Q1 2021 May 13, 2021	BUY	$59.42 - $85.46 $534 - $769	9 Added 0.06%	13,865 $1.07 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $28,813 - $43,518	709 Added 5.39%	13,856 $832,000
Q3 2020 Nov 12, 2020	BUY	$37.76 - $48.49 $189,932 - $243,904	5,030 Added 61.97%	13,147 $566,000
Q2 2020 Aug 13, 2020	BUY	$37.03 - $60.0 $112,571 - $182,400	3,040 Added 59.88%	8,117 $336,000
Q1 2020 May 14, 2020	SELL	$35.02 - $65.64 $2,241 - $4,200	-64 Reduced 1.24%	5,077 $220,000
Q4 2019 Feb 14, 2020	BUY	$33.17 - $65.23 $68,396 - $134,504	2,062 Added 66.97%	5,141 $283,000
Q3 2019 Nov 14, 2019	SELL	$34.72 - $51.3 $66,558 - $98,342	-1,917 Reduced 38.37%	3,079 $105,000
Q2 2019 Aug 14, 2019	SELL	$27.2 - $41.2 $282,281 - $427,573	-10,378 Reduced 67.5%	4,996 $200,000
Q1 2019 May 15, 2019	BUY	$19.86 - $32.9 $305,327 - $505,804	15,374 New	15,374 $505,000
Q4 2018 Feb 14, 2019	SELL	$15.03 - $25.38 $344,637 - $581,963	-22,930 Closed	0 $0
Q3 2018 Dec 21, 2021	BUY	$14.43 - $21.0 $7,215 - $10,500	500 Added 2.23%	22,930 $403,000
Q3 2018 Nov 14, 2018	BUY	$14.43 - $21.0 $323,664 - $471,030	22,430 New	22,430 $394,000

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.57B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account